The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Open accessAbstract
BACKGROUND: IL-13 has an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human mAb that potently and specifically neutralizes IL-13. OBJECTIVE: We sought to evaluate the efficacy and safety of tralokinumab in adults with moderate-to-severe AD. METHODS: In this phase 2b study (NCT02347176), 204 adults were randomized 1:1:1:1 to receive 45, 150, or 300 mg of subcutaneous tralokinumab, or placebo, every 2 weeks for 12 weeks with concomitant topical glucocorticoids. Coprimary end points were change from baseline in Eczema Area Severity Index score and percentage of participants with an Investigator's Global Assessment response (0/1 score and reduction of ≥2 grades from baseline) at week 12. RESULTS: At week 12, 300 mg of tralokinumab significantly improved change from baseline in Eczema Area Severity Index score versus placebo (adjusted mean difference, -4.94; 95% CI, -8.76 to -1.13; P = .01), and a greater percentage of participants achieved an Investigator's Global Assessment response (26.7% vs 11.8%). Greater responses were found in participants with greater concentrations of biomarkers of increased IL-13 activity. Participants treated with 300 mg of tralokinumab demonstrated improvements in SCORAD, Dermatology Life Quality Index, and pruritus numeric rating scale (7-day mean) scores versus placebo. Upper respiratory tract infection was the most frequent treatment-emergent adverse event reported as related to study drug in the placebo (3.9%) and pooled tralokinumab (3.9%) groups. CONCLUSIONS: Tralokinumab treatment was associated with early and sustained improvements in AD symptoms and an acceptable safety and tolerability profile, thereby providing evidence for targeting IL-13 in patients with AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationDupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationDupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Gittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Self-citationNomura, I., Goleva, E., Howell, M. D., Hamid, Q. A., Ong, P. Y., Hall, C. F., Darst, M. A., Gao, B., Boguniewicz, M., Travers, J. B., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3262 · Cited by 731
Self-citationThaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 572
Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches
Leung, D. Y. M., & Guttman-Yassky, E. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.008 · Cited by 474
Self-citationHamilton, J. D., Suárez-Fariñas, M., Dhingra, N., Cardinale, I., Li, X., Kostic, A., Ming, J. E., Radin, A. R., Krueger, J. G., Graham, N., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.013 · Cited by 469
Self-citationWollenberg, A., Oranje, A., Deleuran, M., Simon, D., Szalai, Z., Kunz, B., Svensson, A., Barbarot, S., von Kobyletzki, L., Taieb, A., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13599 · Cited by 395
Self-citationSchram, M. E., Spuls, P. I., Leeflang, M. M. G., Lindeboom, R., Bos, J. D., & Schmitt, J. (2012) · Allergy · doi:10.1111/j.1398-9995.2011.02719.x · Cited by 383
Hanania, N. A., Noonan, M., Corren, J., Korenblat, P., Zheng, Y., Fischer, S. K., Cheu, M., Putnam, W. S., Murray, E., Scheerens, H., et al. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-206719 · Cited by 381
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
Piper, E., Brightling, C., Niven, R., Oh, C., Faggioni, R., Poon, K., She, D., Kell, C., May, R. D., Geba, G. P., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00223411 · Cited by 373
Self-citationBrightling, C. E., Chanez, P., Leigh, R., O'Byrne, P. M., Korn, S., She, D., May, R. D., Streicher, K., Ranade, K., & Piper, E. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00197-6 · Cited by 369
Self-citationSimpson, E. L., Flohr, C., Eichenfield, L. F., Bieber, T., Sofen, H., Taïeb, A., Owen, R., Putnam, W., Castro, M., DeBusk, K., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.017 · Cited by 331
Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease
Poole, A., Urbanek, C., Eng, C., Schageman, J., Jacobson, S., O'Connor, B. P., Galanter, J. M., Gignoux, C. R., Roth, L. A., Kumar, R., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.11.025 · Cited by 260
Tintle, S., Shemer, A., Suárez-Fariñas, M., Fujita, H., Gilleaudeau, P., Sullivan-Whalen, M., Johnson-Huang, L., Chiricozzi, A., Cardinale, I., Duan, S., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.05.042 · Cited by 220
Self-citationEfficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis
Khattri, S., Brunner, P. M., Garcet, S., Finney, R., Cohen, S. R., Oliva, M., Dutt, R., Fuentes‐Duculan, J., Zheng, X., Li, X., et al. (2017) · Experimental Dermatology · doi:10.1111/exd.13112 · Cited by 214
Self-citationAn Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease
Ungar, B., Garcet, S., Gonzalez, J., Dhingra, N., Correa da Rosa, J., Shemer, A., Krueger, J. G., Suarez-Farinas, M., & Guttman-Yassky, E. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.09.037 · Cited by 213
Self-citationKhattri, S., Shemer, A., Rozenblit, M., Dhingra, N., Czarnowicki, T., Finney, R., Gilleaudeau, P., Sullivan-Whalen, M., Zheng, X., Xu, H., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.03.003 · Cited by 180
Self-citationPeriostin in Allergic Inflammation
Izuhara, K., Arima, K., Ohta, S., Suzuki, S., Inamitsu, M., & Yamamoto, K. (2014) · Allergology International · doi:10.2332/allergolint.13-rai-0663 · Cited by 151
Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis
Tazawa, T., Sugiura, H., Sugiura, Y., & Uehara, M. (2004) · Archives of Dermatological Research · doi:10.1007/s00403-004-0455-6 · Cited by 144
May, R. D., Monk, P., Cohen, E. S., Manuel, D. V. F. P., Dempsey, F. C., Davis, N. H. E., Dodd, A., Corkill, D. J., Woods, J. M., Joberty-Candotti, C., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01659.x · Cited by 107
Drug Evaluation Review: Dupilumab in Atopic Dermatitis
Hamilton, J. D., Ungar, B., & Guttman‐Yassky, E. (2015) · Immunotherapy · doi:10.2217/imt.15.69 · Cited by 101
Self-citationPeriostin, a novel biomarker of TH2-driven asthma
Parulekar, A. D., Atik, M., & Hanania, N. A. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000005 · Cited by 100
Singh, D., Kane, B., Molfino, N. A., Faggioni, R., Roskos, L. K., & Woodcock, A. A. (2010) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-10-3 · Cited by 84
Brunner, P. M., Khattri, S., Garcet, S., Finney, R., Oliva, M., Dutt, R., Fuentes‐Duculan, J., Zheng, X., Li, X., Bonifacio, K. M., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1323 · Cited by 77
Self-citationOh, C. K., Faggioni, R., Jin, F., Roskos, L. K., Wang, B., Birrell, C. E., Wilson, R. J., & Molfino, N. A. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03647.x · Cited by 62
Targeting the T Helper 2 Inflammatory Axis in Atopic Dermatitis
Moreno, A. S., McPhee, R. A., Arruda, L. K., & Howell, M. D. (2016) · International Archives of Allergy and Immunology · doi:10.1159/000451083 · Cited by 49
Self-citationGe, M., Durham, L. K., Meyer, R. D., Xie, W., & Thomas, N. (2011) · Drug Information Journal · doi:10.1177/009286151104500409 · Cited by 39
Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing
Baverel, P., Jain, M., Stelmach, I., She, D., Agoram, B. M., Sandbach, S., Piper, E., & Kuna, P. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12725 · Cited by 30
Rozenblit, M., Suárez‐Fariñas, M., Shemer, A., Khattri, S., Gilleaudeau, P., Sullivan-Whalen, M. M., Zheng, X., Xu, H., Cardinale, I. R., Krueger, J. G., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.05.024 · Cited by 22
Self-citation
Cited by
Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J. ‐., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19574 · Cited by 638
Self-citationHe, H., Suryawanshi, H., Morozov, P., Gay-Mimbrera, J., Del Duca, E., Kim, H. J., Kameyama, N., Estrada, Y., Der, E., Krueger, J. G., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.01.042 · Cited by 503
Self-citationWollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
Self-citationTsoi, L. C., Rodriguez, E., Degenhardt, F., Baurecht, H., Wehkamp, U., Volks, N., Szymczak, S., Swindell, W. R., Sarkar, M. K., Raja, K., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.12.018 · Cited by 469
“Consistent with our findings, anti-IL-13 targeted therapy, with tralokinumab, led to early and sustained improvement in AD symptoms(Wollenberg et al., 2018).”
ResultSkin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis
Yang, G., Seok, J. K., Kang, H. C., Cho, Y.-Y., Lee, H. S., & Lee, J. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082867 · Cited by 442
Metadata
- Authors
- Wollenberg, A., Howell, M. D., Guttman-Yassky, E., Silverberg, J. I., Kell, C., Ranade, K., Moate, R., & van der Merwe, R.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 143
- Issue
- 1
- Pages
- 135-141
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2807789068
- Cited by
- 409
- References
- 34
- FWCI
- 48.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.